Prommune Selects Kansas City Animal Health Corridor for Commercial Operations


A 2013 KC Animal Health Investment Forum presenter, growth leads to permanent Corridor location

Overland Park, KS. — May 13, 2015 – Prommune Inc., an animal vaccine research and development company, announced today that it will locate its global commercial operations in Overland Park, Kan., part of the Kansas City Animal Health Corridor.

Dr. Sam Sanderson, founder of Prommune, presented at the 2013 KC Animal Health Investment Forum.  The company’s recent advances and projected growth led to the need to select a permanent location to produce its vaccine products, particularly those to treat Swine Flu and Avian Flu.

Prommune Inc. has entered into an agreement with Babylon BioConsulting LLC to provide executive management and strategic outreach services. Dr. Sam Al-Murrani of Babylon BioConsulting will act as interim chief executive officer for Prommune until a permanent CEO is in place.

“Prommune is proud to select the Kansas City Animal Health Corridor as its permanent home. The Corridor provides unsurpassed logistics, manufacturing and a pool of potential qualified employee mix that a company focused on animal health can ill-afford to ignore,” said Dr. Al-Murrani.

Prommune will initially operate from temporary office space at 9393 West 110th St., in Overland Park. The company expects to hire up to six employees in the first three years with additional marketing and sales personnel added as the company grows.

“Prommune is an excellent example of the reason we host the KC Animal Health Investment Forum each year,” said Kimberly Young, president, KC Animal Health Corridor. “We are very proud of the company’s success and are thrilled to welcome them to the center of the animal health industry as they grow.”

About Prommune, Inc.

Prommune is a research and development company that has created a unique and patented means to safely and effectively awaken the body’s own natural immune defenses without inflammatory side-effects.  Such immune activation is possible through the use of novel immune stimulatory peptides, which are derived from a naturally-occurring protein component of the immune system.  The use of these host-derived immune stimulatory peptides provides a broad therapeutic platform enabling the treatment of normal and antibiotic-resistant infections and the rapid generation a large variety of new vaccines for human and veterinary medicine.

About the KC Animal Health Corridor

Companies with a business location in the KC Animal Health Corridor account for more than half of the sales generated by the global animal health industry. The Corridor, anchored by Manhattan, Kansas, and Columbia, Missouri, is home to more than 300 animal health companies, representing the largest concentration in the world. For more information, visit

#   #   #


Leave A Reply